BY-101 (injectable)

• For treatment of acute myeloid leukemia. (AML
• Through precision medicine to treat first-line AML patients.
• Received USFDA Orphan Drug Designation. (ODD)
• File U.S. and Taiwan FDA IND (Investigational New Drug) in the second quarter of 2021.
• Clinical Phase 2B/3 trials to begin in the second half of 2023.
• Potential market in 2026 is about 1.5 billion USD, with an expected market share of 7~15%.